Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03976336 · ClinicalTrials.gov registry record · NA

Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study

A NA study, sponsored by University of Kansas Medical Center.

Completed
Registry status
NA
Development phase
15
Enrollment target

NCT03976336 is a NA study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03976336, a NA study, has completed, sponsored by University of Kansas Medical Center.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

Berberine is a dietary supplement that comes from the roots, stems, and bark of various plants and has been used for centuries in traditional Chinese medicine. It may help lower cholesterol, lower blood sugar, and reduce inflammation.Very few studies have been done in the United States to show how berberine effects cholesterol and blood sugar. This study is looking to see how berberine changes cholesterol and blood sugar, and to see how well it is tolerated.Berberine is not a prescription medication but it appears to have similar actions to common prescription medications to lower cholesterol like statins, and to lower blood sugar like metformin. We are studying berberine to see if it may be a good option for people that do not want to take prescription medications.

Interventions

  • DIETARY_SUPPLEMENT Berberine
  • OTHER Identical Placebo

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-08-20
Est. Completion 2025-04-01
Phase NA

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT03976336

The ClinicalTrials.gov registry entry for NCT03976336 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Berberine is the first listed.

NCT03976336 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03976336 about?

NCT03976336 is a clinical study titled "Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study". Berberine is a dietary supplement that comes from the roots, stems, and bark of various plants and has been used for centuries in traditional Chinese medicine. It may help lower cholesterol, lower blood sugar, and reduce inflammation.Very few studies have been done in the United States to show how b...

What is the current status of trial NCT03976336?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2019-08-20. Estimated completion is 2025-04-01.

What interventions are being tested in trial NCT03976336?

The interventions under investigation include: Berberine (DIETARY_SUPPLEMENT), Identical Placebo (OTHER).

Who is sponsoring clinical trial NCT03976336?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.